ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
Possible interactions between 5-HT2A receptors and the endocannabinoid system in humans: preliminary evidence of interactive effects of Ayahuasca and Endocannabinoids in a healthy human subject. [Carta] (2018)
Santos, Rafael Guimarães dos ; Crippa, José Alexandre de Souza ; Osório, Flávia de Lima ; Rocha, Juliana Mendes; Rossi, Giordano Novak; Marchioni, Camila; Queiroz, Maria Eugênia Costa ; Silveira, Gabriela de Oliveira; Yonamine, Maurício ; Hallak, Jaime Eduardo Cecílio
Source: Journal of Clinical Psychopharmacology. Unidades: FMRP, FCF, FFCLRP, FCFRP
Subjects: CANABINOIDES, PLANTAS ALUCINÓGENAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Rafael Guimarães dos et al. Possible interactions between 5-HT2A receptors and the endocannabinoid system in humans: preliminary evidence of interactive effects of Ayahuasca and Endocannabinoids in a healthy human subject. [Carta]. Journal of Clinical Psychopharmacology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1097/JCP.0000000000000973. Acesso em: 03 nov. 2024. , 2018
APA
Santos, R. G. dos, Crippa, J. A. de S., Osório, F. de L., Rocha, J. M., Rossi, G. N., Marchioni, C., et al. (2018). Possible interactions between 5-HT2A receptors and the endocannabinoid system in humans: preliminary evidence of interactive effects of Ayahuasca and Endocannabinoids in a healthy human subject. [Carta]. Journal of Clinical Psychopharmacology. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1097/JCP.0000000000000973
NLM
Santos RG dos, Crippa JA de S, Osório F de L, Rocha JM, Rossi GN, Marchioni C, Queiroz MEC, Silveira G de O, Yonamine M, Hallak JEC. Possible interactions between 5-HT2A receptors and the endocannabinoid system in humans: preliminary evidence of interactive effects of Ayahuasca and Endocannabinoids in a healthy human subject. [Carta] [Internet]. Journal of Clinical Psychopharmacology. 2018 ; 38( 6): 644-646.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1097/JCP.0000000000000973
Vancouver
Santos RG dos, Crippa JA de S, Osório F de L, Rocha JM, Rossi GN, Marchioni C, Queiroz MEC, Silveira G de O, Yonamine M, Hallak JEC. Possible interactions between 5-HT2A receptors and the endocannabinoid system in humans: preliminary evidence of interactive effects of Ayahuasca and Endocannabinoids in a healthy human subject. [Carta] [Internet]. Journal of Clinical Psychopharmacology. 2018 ; 38( 6): 644-646.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1097/JCP.0000000000000973
Artigo de periodico
Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos (2018)
Brigante, Tamires Amabile Valim; Abe, Flavia Renata; Zuardi, Antônio Waldo; Hallak, Jaime Eduardo Cecílio; Crippa, José Alexandre de Souza; Oliveira, Danielle Palma de
Source: Chemico-Biological Interactions. Unidades: FMRP, FCFRP
Subjects: ACETILCOLINA, CANABINOIDES, ATIVIDADE MOTORA, TERATOGÊNIOS, FERTILIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRIGANTE, Tamires Amabile Valim et al. Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. Chemico-Biological Interactions, v. 291, p. 81-86, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.cbi.2018.06.008. Acesso em: 03 nov. 2024.
APA
Brigante, T. A. V., Abe, F. R., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. de S., & Oliveira, D. P. de. (2018). Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. Chemico-Biological Interactions, 291, 81-86. doi:10.1016/j.cbi.2018.06.008
NLM
Brigante TAV, Abe FR, Zuardi AW, Hallak JEC, Crippa JA de S, Oliveira DP de. Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos [Internet]. Chemico-Biological Interactions. 2018 ; 291 81-86.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.cbi.2018.06.008
Vancouver
Brigante TAV, Abe FR, Zuardi AW, Hallak JEC, Crippa JA de S, Oliveira DP de. Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos [Internet]. Chemico-Biological Interactions. 2018 ; 291 81-86.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.cbi.2018.06.008
Artigo de periodico
Rimonabant effects on anxiety induced by simulated public speaking in health humans: a preliminary report (2014)
Bergamaschi, Mateus M.; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; Linares, Ila M. P.; Arrais, Kátia C.; Oliveira, Danielle C. G. de; Queiroz, Maria Eugênia Costa; Nardi, Antonio E.; Huestis, Marilyn A.; Hallak, Jaime Eduardo Cecílio; Zuardi, Antonio Waldo; Moreira, Fabrício A.; Crippa, José Alexandre de Souza
Source: Human Psychopharmacology. Unidades: FCFRP, FMRP, FFCLRP
Subjects: CANNABIS (COMPONENTES), ANTAGONISTAS, ANSIEDADE (TESTES)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERGAMASCHI, Mateus M. et al. Rimonabant effects on anxiety induced by simulated public speaking in health humans: a preliminary report. Human Psychopharmacology, v. 29, n. 1, p. 94-99, 2014Tradução . . Disponível em: https://doi.org/10.1002/hup.2374. Acesso em: 03 nov. 2024.
APA
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., Linares, I. M. P., Arrais, K. C., Oliveira, D. C. G. de, et al. (2014). Rimonabant effects on anxiety induced by simulated public speaking in health humans: a preliminary report. Human Psychopharmacology, 29( 1), 94-99. doi:10.1002/hup.2374
NLM
Bergamaschi MM, Queiroz RHC, Chagas MHN, Linares IMP, Arrais KC, Oliveira DCG de, Queiroz MEC, Nardi AE, Huestis MA, Hallak JEC, Zuardi AW, Moreira FA, Crippa JA de S. Rimonabant effects on anxiety induced by simulated public speaking in health humans: a preliminary report [Internet]. Human Psychopharmacology. 2014 ; 29( 1): 94-99.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1002/hup.2374
Vancouver
Bergamaschi MM, Queiroz RHC, Chagas MHN, Linares IMP, Arrais KC, Oliveira DCG de, Queiroz MEC, Nardi AE, Huestis MA, Hallak JEC, Zuardi AW, Moreira FA, Crippa JA de S. Rimonabant effects on anxiety induced by simulated public speaking in health humans: a preliminary report [Internet]. Human Psychopharmacology. 2014 ; 29( 1): 94-99.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1002/hup.2374
Artigo de periodico
Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up (2014)
Balbão, Marina Salviato; Hallak, Jaime Eduardo Cecílio; Nunes, Emerson Arcoverde; Mello, Mauricio Homem de; Triffoni-Melo, Andresa de Toledo; Ferreira, Flavia Isaura de Santi; Chaves, Cristiano; Durão, Ana Maria Sertori; Ramos, Adriana Pelegrino Pinho; Crippa, José Alexandre de Souza; Queiroz, Regina Helena Costa
Source: Therapeutic Advances in Psychopharmacology. Unidades: FMRP, FCFRP
Subjects: ANTIPSICÓTICOS (EFEITOS ADVERSOS), GANHO DE PESO, ANTROPOMETRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BALBÃO, Marina Salviato et al. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology, v. 4, n. 1, p. 30-36, 2014Tradução . . Disponível em: https://doi.org/10.1177/2045125313507738. Acesso em: 03 nov. 2024.
APA
Balbão, M. S., Hallak, J. E. C., Nunes, E. A., Mello, M. H. de, Triffoni-Melo, A. de T., Ferreira, F. I. de S., et al. (2014). Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology, 4( 1), 30-36. doi:10.1177/2045125313507738
NLM
Balbão MS, Hallak JEC, Nunes EA, Mello MH de, Triffoni-Melo A de T, Ferreira FI de S, Chaves C, Durão AMS, Ramos APP, Crippa JA de S, Queiroz RHC. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up [Internet]. Therapeutic Advances in Psychopharmacology. 2014 ; 4( 1): 30-36.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1177/2045125313507738
Vancouver
Balbão MS, Hallak JEC, Nunes EA, Mello MH de, Triffoni-Melo A de T, Ferreira FI de S, Chaves C, Durão AMS, Ramos APP, Crippa JA de S, Queiroz RHC. Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up [Internet]. Therapeutic Advances in Psychopharmacology. 2014 ; 4( 1): 30-36.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1177/2045125313507738
Artigo de periodico
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report (2013)
Crippa, José Alexandre de Souza; Hallak, Jaime Eduardo Cecílio; Machado-de-Sousa, J. P; Queiroz, Regina Helena Costa; Bergamaschi, M; Chagas, Marcos Hortes Nisihara; Zuardi, Antonio Waldo
Source: Journal of Clinical Pharmacy and Therapeutics. Unidades: FMRP, FCFRP
Subjects: CANNABIS (APLICAÇÕES TERAPÊUTICAS;EFEITOS ADVERSOS), TRANSTORNOS RELACIONADOS AO USO DE SUBSTÂNCIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. Journal of Clinical Pharmacy and Therapeutics, v. 38, n. 2, p. 162-164, 2013Tradução . . Disponível em: https://doi.org/10.1111/jcpt.12018. Acesso em: 03 nov. 2024.
APA
Crippa, J. A. de S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013). Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. Journal of Clinical Pharmacy and Therapeutics, 38( 2), 162-164. doi:10.1111/jcpt.12018
NLM
Crippa JA de S, Hallak JEC, Machado-de-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2013 ; 38( 2): 162-164.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1111/jcpt.12018
Vancouver
Crippa JA de S, Hallak JEC, Machado-de-Sousa JP, Queiroz RHC, Bergamaschi M, Chagas MHN, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report [Internet]. Journal of Clinical Pharmacy and Therapeutics. 2013 ; 38( 2): 162-164.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1111/jcpt.12018
Trabalho de evento-resumo
Mechanism of action of weight gain in schizophrenic patients on olanzapine therapy (2011)
Balbão, M. S.; Hallak, Jaime Eduardo Cecílio; Arantes, Eliane Candiani; Dreossi, Sonia Aparecida Carvalho; Queiróz, Regina Helena Costa
Source: Abstracts. Conference titles: International Congress of Pharmaceutical Sciences (CIFARP). Unidades: FCFRP, FMRP
Subjects: ESQUIZOFRENIA, OBESIDADE, PEPTÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BALBÃO, M. S. et al. Mechanism of action of weight gain in schizophrenic patients on olanzapine therapy. 2011, Anais.. Ribeirão Preto: FCFRP, Associação Brasileira de Ciências Farmacêuticas, 2011. . Acesso em: 03 nov. 2024.
APA
Balbão, M. S., Hallak, J. E. C., Arantes, E. C., Dreossi, S. A. C., & Queiróz, R. H. C. (2011). Mechanism of action of weight gain in schizophrenic patients on olanzapine therapy. In Abstracts. Ribeirão Preto: FCFRP, Associação Brasileira de Ciências Farmacêuticas.
NLM
Balbão MS, Hallak JEC, Arantes EC, Dreossi SAC, Queiróz RHC. Mechanism of action of weight gain in schizophrenic patients on olanzapine therapy. Abstracts. 2011 ;[citado 2024 nov. 03 ]
Vancouver
Balbão MS, Hallak JEC, Arantes EC, Dreossi SAC, Queiróz RHC. Mechanism of action of weight gain in schizophrenic patients on olanzapine therapy. Abstracts. 2011 ;[citado 2024 nov. 03 ]
Artigo de periodico
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Naïve social phobia patients (2011)
Bergamaschi, Mateus M.; Queiroz, Regina Helena Costa; Chagas, Marcos Hortes Nisihara; Oliveira, Danielle Chaves Gomes de; De Martinis, Bruno Spinosa; Kapczinski, Flávio; Quevedo, João; Roesler, Rafael; Schröder, Nadja; Nardi, Antonio E.; Martín-Santos, Rocio; Hallak, Jaime Eduardo Cecílio; Zuardi, Antonio Waldo; Crippa, José Alexandre de Souza
Source: Neuropsychopharmacology. Unidades: FMRP, FFCLRP, FCFRP
Subjects: CANNABIS (EFEITOS), ANSIOLÍTICOS, FOBIA SOCIAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERGAMASCHI, Mateus M. et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Naïve social phobia patients. Neuropsychopharmacology, v. 36, n. 6, p. 1219-1226, 2011Tradução . . Acesso em: 03 nov. 2024.
APA
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., Oliveira, D. C. G. de, De Martinis, B. S., Kapczinski, F., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Naïve social phobia patients. Neuropsychopharmacology, 36( 6), 1219-1226.
NLM
Bergamaschi MM, Queiroz RHC, Chagas MHN, Oliveira DCG de, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Naïve social phobia patients. Neuropsychopharmacology. 2011 ; 36( 6): 1219-1226.[citado 2024 nov. 03 ]
Vancouver
Bergamaschi MM, Queiroz RHC, Chagas MHN, Oliveira DCG de, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JA de S. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-Naïve social phobia patients. Neuropsychopharmacology. 2011 ; 36( 6): 1219-1226.[citado 2024 nov. 03 ]
Artigo de periodico
Development and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma (2011)
Camargo, Stefania Pimenta Serrambana; Queiroz, Regina Helena Costa; Malfará, Wilson Roberto; Crippa, José Alexandre de Souza; Zuardi, Antonio Waldo; Hallak, Jaime Eduardo Cecílio; De Martinis, Bruno Spinosa
Source: Current Pharmaceutical Analysis. Unidades: FCFRP, FMRP, FFCLRP
Subjects: CANNABIS (COMPONENTES;EFEITOS), PLASMA, USOS TERAPÊUTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAMARGO, Stefania Pimenta Serrambana et al. Development and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma. Current Pharmaceutical Analysis, v. 7, n. 4, p. 228-234, 2011Tradução . . Acesso em: 03 nov. 2024.
APA
Camargo, S. P. S., Queiroz, R. H. C., Malfará, W. R., Crippa, J. A. de S., Zuardi, A. W., Hallak, J. E. C., & De Martinis, B. S. (2011). Development and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma. Current Pharmaceutical Analysis, 7( 4), 228-234.
NLM
Camargo SPS, Queiroz RHC, Malfará WR, Crippa JA de S, Zuardi AW, Hallak JEC, De Martinis BS. Development and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma. Current Pharmaceutical Analysis. 2011 ; 7( 4): 228-234.[citado 2024 nov. 03 ]
Vancouver
Camargo SPS, Queiroz RHC, Malfará WR, Crippa JA de S, Zuardi AW, Hallak JEC, De Martinis BS. Development and validation of a liquid-liquid extraction and gas chromatography/mass spectrometry methodology for cannabidiol analysis in human plasma. Current Pharmaceutical Analysis. 2011 ; 7( 4): 228-234.[citado 2024 nov. 03 ]
Trabalho de evento-resumo periodico
Anxiolytic effect of cannabidiol in subjects with social anxiety disorder (2010)
Bergamaschi, M. M.; Chagas, M. H. N.; Chaves, D. I.; Martinis, Bruno Spinosa de; Grando, M. D.; Freitas, M. C.; Queiroz, Regina Helena Costa; Hallak, Jaime Eduardo Cecílio; Zuardi, Antonio Waldo; Crippa, José Alexandre de Souza
Source: European Neuropsychopharmacology. Conference titles: Congress of the European College of Neuropsychopharmacology (ECNP). Unidades: FMRP, FFCLRP, FCFRP
Subjects: CANNABIS, ANSIOLÍTICOS, EXTRATOS (FORMAS FARMACÊUTICAS)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BERGAMASCHI, M. M. et al. Anxiolytic effect of cannabidiol in subjects with social anxiety disorder. European Neuropsychopharmacology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 03 nov. 2024. , 2010
APA
Bergamaschi, M. M., Chagas, M. H. N., Chaves, D. I., Martinis, B. S. de, Grando, M. D., Freitas, M. C., et al. (2010). Anxiolytic effect of cannabidiol in subjects with social anxiety disorder. European Neuropsychopharmacology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
NLM
Bergamaschi MM, Chagas MHN, Chaves DI, Martinis BS de, Grando MD, Freitas MC, Queiroz RHC, Hallak JEC, Zuardi AW, Crippa JA de S. Anxiolytic effect of cannabidiol in subjects with social anxiety disorder. European Neuropsychopharmacology. 2010 ; 20 S542.[citado 2024 nov. 03 ]
Vancouver
Bergamaschi MM, Chagas MHN, Chaves DI, Martinis BS de, Grando MD, Freitas MC, Queiroz RHC, Hallak JEC, Zuardi AW, Crippa JA de S. Anxiolytic effect of cannabidiol in subjects with social anxiety disorder. European Neuropsychopharmacology. 2010 ; 20 S542.[citado 2024 nov. 03 ]
Trabalho de evento-resumo
Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine (2010)
Balbão, Marina Salviato; Melo, Maurício Homem de; Triffoni, Andresa de Toledo; Hallak, Jaime Eduardo Cecílio; Durão, Ana Maria; Ramos, Adriana Pelegrino Pinho; Queiróz, Regina Helena Costa
Source: Resumos. Conference titles: Simpósio Internacional de Pós-Graduação e Pesquisa (SINPOSPq). Unidades: FCFRP, FMRP
Assunto: ESQUIZOFRENIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BALBÃO, Marina Salviato et al. Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine. 2010, Anais.. Ribeirão Preto: FCFRP-USP, 2010. . Acesso em: 03 nov. 2024.
APA
Balbão, M. S., Melo, M. H. de, Triffoni, A. de T., Hallak, J. E. C., Durão, A. M., Ramos, A. P. P., & Queiróz, R. H. C. (2010). Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine. In Resumos. Ribeirão Preto: FCFRP-USP.
NLM
Balbão MS, Melo MH de, Triffoni A de T, Hallak JEC, Durão AM, Ramos APP, Queiróz RHC. Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine. Resumos. 2010 ;[citado 2024 nov. 03 ]
Vancouver
Balbão MS, Melo MH de, Triffoni A de T, Hallak JEC, Durão AM, Ramos APP, Queiróz RHC. Cardiac risk assessment in schizophrenic patients in treatment with the olanzapine. Resumos. 2010 ;[citado 2024 nov. 03 ]
Trabalho de evento-resumo
Cannabidiol (CBD) for the treatment of bipolar affective disorder (2007)
Crippa, José Alexandre de Souza; Hallak, Jaime Eduardo Cecílio; Vilela, José Antônio Alves; Morais, Silvio L.; Sanches, Rafael Faria; Malfará, Wilson; Camargo, Stefania Pimenta S.; Musty, Richard E.; Queiroz, Regina Helena Costa; Zuardi, Antonio Waldo
Source: Program and Abstracts. Conference titles: Annual Symposium on the Cannabinoids. Unidades: FMRP, FCFRP
Subjects: TRANSTORNO BIPOLAR, CANNABIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol (CBD) for the treatment of bipolar affective disorder. 2007, Anais.. Québec: International Cannabinoid Research Society, 2007. . Acesso em: 03 nov. 2024.
APA
Crippa, J. A. de S., Hallak, J. E. C., Vilela, J. A. A., Morais, S. L., Sanches, R. F., Malfará, W., et al. (2007). Cannabidiol (CBD) for the treatment of bipolar affective disorder. In Program and Abstracts. Québec: International Cannabinoid Research Society.
NLM
Crippa JA de S, Hallak JEC, Vilela JAA, Morais SL, Sanches RF, Malfará W, Camargo SPS, Musty RE, Queiroz RHC, Zuardi AW. Cannabidiol (CBD) for the treatment of bipolar affective disorder. Program and Abstracts. 2007 ;[citado 2024 nov. 03 ]
Vancouver
Crippa JA de S, Hallak JEC, Vilela JAA, Morais SL, Sanches RF, Malfará W, Camargo SPS, Musty RE, Queiroz RHC, Zuardi AW. Cannabidiol (CBD) for the treatment of bipolar affective disorder. Program and Abstracts. 2007 ;[citado 2024 nov. 03 ]

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Indexado em

Non normalized affiliation